Jacobsen M, Petersen J, Modin D, Butt J, Thune J, Bundgaard H
Am Heart J Plus. 2024; 25:100244.
PMID: 38510499
PMC: 10946047.
DOI: 10.1016/j.ahjo.2022.100244.
Lu J, Fan Z, Li Y, Wang Z, Ma L, Yuan B
Front Cardiovasc Med. 2022; 9:1054199.
PMID: 36568560
PMC: 9772473.
DOI: 10.3389/fcvm.2022.1054199.
Butzner M, Rowin E, Yakubu A, Seale J, Robertson L, Sarocco P
J Clin Med. 2022; 11(13).
PMID: 35807183
PMC: 9267176.
DOI: 10.3390/jcm11133898.
Mandes L, Rosca M, Ciuperca D, Popescu B
J Echocardiogr. 2020; 18(3):137-148.
PMID: 32301048
PMC: 7473965.
DOI: 10.1007/s12574-020-00467-9.
Songsirisuk N, Kittipibul V, Methachittiphan N, Charoenattasil V, Zungsontiporn N, Spanuchart I
BMC Cardiovasc Disord. 2019; 19(1):1.
PMID: 30606129
PMC: 6318850.
DOI: 10.1186/s12872-018-0984-0.
Interrelationship Between Kidney Function and Percutaneous Mitral Valve Interventions: A Comprehensive Review.
Lo K, Dayanand S, Ram P, Dayanand P, Slipczuk L, Figueredo V
Curr Cardiol Rev. 2018; 15(2):76-82.
PMID: 30360746
PMC: 6520580.
DOI: 10.2174/1573403X14666181024155247.
Women with hypertrophic cardiomyopathy have worse survival.
Geske J, Ong K, Siontis K, Hebl V, Ackerman M, Hodge D
Eur Heart J. 2017; 38(46):3434-3440.
PMID: 29020402
PMC: 6251550.
DOI: 10.1093/eurheartj/ehx527.
Hypertrophic cardiomyopathy in daily practice: an introduction on diagnosis, prognosis and treatment.
van der Lee C, Kofflard M, Geleijnse M, Ten Cate F
Neth Heart J. 2015; 13(12):452-460.
PMID: 25696443
PMC: 2497370.
Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy.
Elliott P, Gimeno J, Thaman R, Shah J, Ward D, Dickie S
Heart. 2005; 92(6):785-91.
PMID: 16216855
PMC: 1860645.
DOI: 10.1136/hrt.2005.068577.
Percutaneous transluminal septal reduction for hypertrophic obstructive cardiomyopathy: report from an international pilot study.
Buell H, Stables R, DeLong E, Shuping K, Killip D, Lever H
J Med Syst. 2002; 26(4):293-300.
PMID: 12118813
DOI: 10.1023/a:1015812603042.
The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era.
Elliott P
Curr Cardiol Rep. 2001; 3(2):167-72.
PMID: 11177676
DOI: 10.1007/s11886-001-0045-6.
Natural history of hypertrophic cardiomyopathy.
Elliott P
Curr Cardiol Rep. 2000; 2(2):141-7.
PMID: 10980885
DOI: 10.1007/s11886-000-0011-8.
Hypertrophic obstructive cardiomyopathy: alternative therapeutic options.
Lakkis N, Kleiman N, Killip D, Spencer 3rd W
Clin Cardiol. 1997; 20(5):417-8.
PMID: 9134270
PMC: 6655986.
DOI: 10.1002/clc.4960200503.
Left ventricular chamber dilatation in hypertrophic cardiomyopathy: related variables and prognosis in patients with medical and surgical therapy.
Seiler C, Jenni R, Vassalli G, Turina M, Hess O
Br Heart J. 1995; 74(5):508-16.
PMID: 8562235
PMC: 484070.
DOI: 10.1136/hrt.74.5.508.
Hypertrophic cardiomyopathy, ten years' experience.
Kenny J, McCarthy C, Blake S, McCann P, COUNIHAN T
Ir J Med Sci. 1987; 156(2):56-60.
PMID: 3570701
DOI: 10.1007/BF02976420.
